Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-05-14
- Target Recruit Count
- 43
- Registration Number
- NCT01743482
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 6
- Registration Number
- NCT01719302
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 51
- Registration Number
- NCT01716546
- Locations
- 🇬🇷
401 Military Hospital of Athens, Athens, Greece
🇬🇷"Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece
🇬🇷"IASO" General Hospital of Athens, Athens, Greece
Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Interventions
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 32
- Registration Number
- NCT01716416
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 58
- Registration Number
- NCT01713296
- Locations
- 🇬🇷
Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷"Papageorgiou" Hospital of Thessaloniki, Thessaloniki, Greece
🇬🇷"IASO" General Hospital of Athens, Athens, Greece
Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 52
- Registration Number
- NCT01692496
- Locations
- 🇪🇸
Instituto Valenciano de Oncología, Valencia, Spain
🇪🇸Hospital Universitario de Canarias, La Laguna, Islas Canarias, Spain
🇩🇪Universitätsmedizin Mannheim (Sarkomzentrum), Manheim, Germany
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 662
- Registration Number
- NCT01649778
- Locations
- 🇬🇧
Novartis Investigative Site, Shrewsbury, United Kingdom
Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 72
- Registration Number
- NCT01644825
- Locations
- 🇮🇹
Ospedale Bellaria, Bologna, Italy
🇮🇹Ospedale Senatore Antonio Perrino, Brindisi, Italy
🇮🇹Seconda Universita di Napoli, Napoli, Italy
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 18
- Registration Number
- NCT01642017
- Locations
- 🇫🇷
Hôpital Saint André, Bordeaux, France
🇫🇷Centre François BACLESSE, Caen, France
🇫🇷Institut Claudius REGAUD, Toulouse, France
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 28
- Registration Number
- NCT01639911
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.